AAPS/RAPS/CAPRA Collaborative Program: Exploring the Challenges of Drug Regulation in a Global Environment: Clinical Concerns

Overview

Journal AAPS PharmSci

Specialty Pharmacology

Date 2004 Jun 17

PMID 15198515

Authors

Marilyn N Martinez

Iain McGilveray

Affiliations

Soon will be listed here.

Abstract

Globalization of the pharmaceutical industry has led to a need to harmonize the regulatory requirements governing the marketing of medicinal products. To minimize the barriers impeding global drug product registration, the International Conference on the Harmonization of Technical Requirements of Pharmaceuticals for Human Use (ICH) was established in 1990. The ICH has developed a series of guidelines that reflect agreements reached by participating nations on aspects of the chemistry and clinical technical sections that will fulfill the regulatory requirements of these various jurisdications. Nevertheless, there continue to be points of divergent perspectives and barriers that can impede the use of foreign clinical data. Given the importance of these issues, the Regulatory Science (RS) section of the American Association of Pharmaceutical Scientists (AAPS), in conjunction with the Regulatory Affairs Professional Society (RAPS) and the Canadian Association of Professional Regulatory Affairs (CAPRA) cosponsored a public forum on this topic. This manuscript provides a summary of the speaker presentations and audience discussions regarding the design of clinical trials and the extrapolation of results from these trials to support international drug registration.

References

Meis J, Petrou M, Bille J, Ellis D, Gibbs D . A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance Group. Diagn Microbiol Infect Dis. 2000; 36(4):215-23. DOI: 10.1016/s0732-8893(99)00152-2. View

Graf J, Doig G, Cook D, Vincent J, Sibbald W . Randomized, controlled clinical trials in sepsis: has methodological quality improved over time?. Crit Care Med. 2002; 30(2):461-72. DOI: 10.1097/00003246-200202000-00032. View

Talley N, Stanghellini V, Heading R, Koch K, Malagelada J, Tytgat G . Functional gastroduodenal disorders. Gut. 1999; 45 Suppl 2:II37-42. PMC: 1766695. DOI: 10.1136/gut.45.2008.ii37. View

OShea J, DeMets D . Statistical issues relating to international differences in clinical trials. Am Heart J. 2001; 142(1):21-8. DOI: 10.1067/mhj.2001.116275. View

Ross P, Huang C . Hip fracture incidence among Caucasians in Hawaii is similar to Japanese. A population-based study. Aging (Milano). 2000; 12(5):356-9. DOI: 10.1007/BF03339860. View

Patriarca P, Wright P, John T . Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991; 13(5):926-39. DOI: 10.1093/clinids/13.5.926. View

Rouleau J, Moye L, Pfeffer M, Arnold J, Bernstein V, Cuddy T . A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N Engl J Med. 1993; 328(11):779-84. DOI: 10.1056/NEJM199303183281108. View

Kottakis J, Wood R, Le Gros V, Della Cioppa G . Clinical efficacy with formoterol in the absence of a response to salmeterol: a review. Int J Clin Pract. 2001; 55(7):476-9. View

. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 1998; 114(3):579-81. DOI: 10.1016/s0016-5085(98)70541-4. View

10.

Rutledge D . Race and hypertension. What is clinically relevant?. Drugs. 1994; 47(6):914-32. DOI: 10.2165/00003495-199447060-00005. View

11.

Akkerhuis K, Deckers J, Boersma E, Harrington R, Stepinska J, Mahaffey K . Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J. 2000; 21(5):371-81. DOI: 10.1053/euhj.1999.1743. View

12.

Hunt R, Fallone C, Thomson A . Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol. 1999; 13(3):213-7. DOI: 10.1155/1999/180751. View

13.

White H . International differences: selection, noise, or real?. Eur Heart J. 2000; 21(5):339-42. DOI: 10.1053/euhj.1999.1925. View

14.

Ono S, Kodama Y, Nagao T, Toyoshima S . The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections. Control Clin Trials. 2002; 23(1):29-41. DOI: 10.1016/s0197-2456(01)00182-9. View

15.

Palmer L, Silverman E, Weiss S, Drazen J . Pharmacogenetics of asthma. Am J Respir Crit Care Med. 2002; 165(7):861-6. DOI: 10.1164/ajrccm.165.7.2109096. View

16.

Liebowitz L, Ashbee H, EVANS E, Chong Y, Mallatova N, Zaidi M . A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn Microbiol Infect Dis. 2001; 40(1-2):27-33. DOI: 10.1016/s0732-8893(01)00243-7. View

17.

Graham I, Beardall S, Carter A, Glennie J, Hebert P, Tetroe J . What is the quality of drug therapy clinical practice guidelines in Canada?. CMAJ. 2001; 165(2):157-63. PMC: 81282. View

18.

OShea J, Califf R . International differences in treatment effects in cardiovascular clinical trials. Am Heart J. 2001; 141(5):875-80. DOI: 10.1067/mhj.2001.115186. View

19.

Davidson J, Gadde K, Fairbank J, Krishnan K, Califf R, Binanay C . Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002; 287(14):1807-14. DOI: 10.1001/jama.287.14.1807. View

20.

OShea J, Califf R . International differences in cardiovascular clinical trials. Am Heart J. 2001; 141(5):866-74. DOI: 10.1067/mhj.2001.114982. View